Abstract
This case-control study investigated the interactions between genetic and environmental factors and inhibitor development in 108 children with haemophilia A exclusively treated with recombinant factor VIII (FVIII). Sixty patients with inhibitors were compared with 48 inhibitor-free controls. Family history of inhibitors and null mutations in the FVIII gene were more prevalent in cases than in controls (20% vs. 2%, P = 0·001 and 83% vs. 64%, P = 0·04, respectively). On the other hand, there was no difference between cases and controls for such putative risk factors of inhibitor development as amniocentesis/villocentesis, premature/caesarean birth, breast-feeding, treatment during infections/vaccinations, surgical procedures and central nervous system bleeding. A trend was found for an increased risk of inhibitor development in children first treated at a young age (
| Original language | English |
|---|---|
| Pages (from-to) | 422-427 |
| Number of pages | 6 |
| Journal | British Journal of Haematology |
| Volume | 130 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Aug 2005 |
Fingerprint
Keywords
- FVIII gene mutations
- Haemophilia
- Inhibitors
- Prophylaxis
- Risk factors
ASJC Scopus subject areas
- Hematology
Cite this
Environmental risk factors for inhibitor development in children with haemophilia A : A case-control study. / Santagostino, Elena; Mancuso, Maria Elisa; Rocino, Angiola; Mancuso, Giacomo; Mazzucconi, Maria Gabriella; Tagliaferri, Annarita; Messina, Maria; Mannucci, Pier Mannuccio.
In: British Journal of Haematology, Vol. 130, No. 3, 08.2005, p. 422-427.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Environmental risk factors for inhibitor development in children with haemophilia A
T2 - A case-control study
AU - Santagostino, Elena
AU - Mancuso, Maria Elisa
AU - Rocino, Angiola
AU - Mancuso, Giacomo
AU - Mazzucconi, Maria Gabriella
AU - Tagliaferri, Annarita
AU - Messina, Maria
AU - Mannucci, Pier Mannuccio
PY - 2005/8
Y1 - 2005/8
N2 - This case-control study investigated the interactions between genetic and environmental factors and inhibitor development in 108 children with haemophilia A exclusively treated with recombinant factor VIII (FVIII). Sixty patients with inhibitors were compared with 48 inhibitor-free controls. Family history of inhibitors and null mutations in the FVIII gene were more prevalent in cases than in controls (20% vs. 2%, P = 0·001 and 83% vs. 64%, P = 0·04, respectively). On the other hand, there was no difference between cases and controls for such putative risk factors of inhibitor development as amniocentesis/villocentesis, premature/caesarean birth, breast-feeding, treatment during infections/vaccinations, surgical procedures and central nervous system bleeding. A trend was found for an increased risk of inhibitor development in children first treated at a young age (
AB - This case-control study investigated the interactions between genetic and environmental factors and inhibitor development in 108 children with haemophilia A exclusively treated with recombinant factor VIII (FVIII). Sixty patients with inhibitors were compared with 48 inhibitor-free controls. Family history of inhibitors and null mutations in the FVIII gene were more prevalent in cases than in controls (20% vs. 2%, P = 0·001 and 83% vs. 64%, P = 0·04, respectively). On the other hand, there was no difference between cases and controls for such putative risk factors of inhibitor development as amniocentesis/villocentesis, premature/caesarean birth, breast-feeding, treatment during infections/vaccinations, surgical procedures and central nervous system bleeding. A trend was found for an increased risk of inhibitor development in children first treated at a young age (
KW - FVIII gene mutations
KW - Haemophilia
KW - Inhibitors
KW - Prophylaxis
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=24944440876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24944440876&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2005.05605.x
DO - 10.1111/j.1365-2141.2005.05605.x
M3 - Article
VL - 130
SP - 422
EP - 427
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 3
ER -